Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1239 Results

Title
Intervention Indication Therapeutic Area Year Actions
Darolutamide with androgen deprivation therapy for metastatic hormone sensitive prostate cancer Darolutamide (ODM-201; BAY-1841788; Nubeqa) Prostate cancer Male Reproductive Cancer 2024 View  |  Download
Darolutamide in addition to docetaxel and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer Darolutamide (ODM-201; BAY-1841788; Nubeqa) , Docetaxel (Taxotere; docetaxel trihydrate; docetaxel anhydrous) Prostate cancer Male Reproductive Cancer 2021 View  |  Download
Darolutamide for Non‐metastatic, Castration-resistant Prostate Cancer Darolutamide (ODM-201; BAY-1841788; Nubeqa) Prostate cancer Male Reproductive Cancer 2018 View  |  Download
Daridorexant for Insomnia Daridorexant (ACT-541468; Nemorexant) Insomnia Neurology 2020 View  |  Download
Darbepoetin alfa (Aranesp) for treatment of anaemia in adults with low or intermediate-1-risk myelodysplastic syndromes Darbepoetin alfa (Aranesp) Anaemia Haematology 2017 View  |  Download
Daratumumab with bortezomib, lenalidomide and dexamethasone for previously untreated transplant eligible multiple myeloma Bortezomib (Velcade; bortezomib mannitol boronic ester) , Daratumumab (Darzalex; JNJ-54767414) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Lenalidomide (Revlimid) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2022 View  |  Download
Daratumumab in combination with Bortezomib, Melphalan and Prednisone for Multiple Myeloma – first line Bortezomib (Velcade; bortezomib mannitol boronic ester) , Daratumumab (Darzalex; JNJ-54767414) , Melphalan , Prednisone (Decadron; Lodotra) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2018 View  |  Download
Daratumumab in addition to pomalidomide and dexamethasone for relapsed or refractory multiple myeloma Daratumumab (Darzalex; JNJ-54767414) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Pomalidomide (Imnovid; CC-4047; Pomalyst) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2020 View  |  Download
Daratumumab in addition to cyclophosphamide, bortezomib and dexamethasone for newly diagnosed systemic amyloid light-chain amyloidosis Bortezomib (Velcade; bortezomib mannitol boronic ester) , Cyclophosphamide (Procytox; cyclophosphamide monohydrate) , Daratumumab (Darzalex; JNJ-54767414) , Dexamethasone (dexamethasone sodium metasulfobenzoate) Amyloidosis Endocrine Nutritional and Metabolic Disorders 2020 View  |  Download
Daratumumab in addition to Bortezomib, Thalidomide and Dexamethasone for newly diagnosed Multiple Myeloma Bortezomib (Velcade; bortezomib mannitol boronic ester) , Daratumumab (Darzalex; JNJ-54767414) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Thalidomide (Taldo) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2018 View  |  Download
1 2 94 95 96 97 98 123 124
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications